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Background: Discovering new lead compounds against malaria parasites is a crucial step to ensuring a sustainable
global pipeline for effective anti-malarial drugs. As far as we know, no previous phytochemical or pharmacological
investigations have been carried out on Sorindeia juglandifolia. This paper describes the results of an anti-malarial
activity-driven investigation of the fruits of this Cameroonian plant.
Methods: Air-dried fruits were extracted by maceration using methanol. The extract was fractionated by flash
chromatography followed by column chromatography over silica gel, eluting with gradients of hexane-ethyl
acetate mixtures. Resulting fractions and compounds were tested in vitro against the Plasmodium falciparum
chloroquine-resistant strain W2, against field isolates of P. falciparum, and against the P. falciparum recombinant
cysteine protease falcipain-2. Promising fractions were assessed for acute toxicity after oral administration in mice.
One of the promising isolated compounds was assessed in vivo against the rodent malaria parasite Plasmodium
berghei.
Results: The main end-products of the activity-guided fractionation were 2,3,6-trihydroxy benzoic acid (1) and
2,3,6-trihydroxy methyl benzoate (2). Overall, nine fractions tested against P. falciparum W2 and falcipain-2 were
active, with IC50 values of 2.3-11.6 μg/ml for W2, and 1.1-21.9 μg/ml for falcipain-2. Purified compounds (1) and (2)
also showed inhibitory effects against P. falciparum W2 (IC50s 16.5 μM and 13.0 μM) and falcipain-2 (IC50s 35.4 and
6.1 μM). In studies of P. falciparum isolates from Cameroon, the plant fractions demonstrated IC50 values of
0.14-19.4 μg/ml and compounds (1) and (2) values of 6.3 and 36.1 μM. In vivo assessment of compound (1) showed
activity against P. berghei strain B, with mean parasitaemia suppressive dose and curative dose of 44.9 mg/kg
and 42.2 mg/kg, respectively. Active fractions were found to be safe in mice after oral administration of
7 g/kg body weight.
Conclusions: Fractions of Sorindeia juglandifolia and two compounds isolated from these fractions were active
against cultured malaria parasites, the P. falciparum protease falcipain-2, and in a rodent malaria model. These
results suggest that further investigation of the anti-malarial activities of natural products from S. juglandifolia will
be appropriate.
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Despite extensive recent efforts to control malaria, it
remains a major public health threat throughout the tro-
pics. Annually, 500 million people are at risk of malaria,
and about one million deaths occur, primarily from disease
caused by Plasmodium falciparum, and mostly in preg-
nant women and children under five years of age. With
persistent severe malarial morbidity and increasing resist-
ance to malaria drugs, including possibly new artemisinin-
based combination therapy (ACT) [1], there is a compel-
ling need for new and improved treatments for malaria.
Therefore, a vibrant drug discovery pipeline is needed to
ensure the availability of new effective anti-malarials.
The nations of Sub-Saharan Africa have the greatest
burden of malaria, and also vital resources, that is diver-
sified and rich floras on which their traditional medi-
cines depend. Considering important roles for natural
products in the treatment of malaria, the screening of
medicinal plants to search for novel chemical entities
with activity against malaria parasites is a credible ap-
proach to discover new anti-malarial leads. In this paper,
the results of investigation of the fruits of Sorindeia
juglandifolia (Anacardiaceae) growing in Cameroon as a
source of anti-malarial agents are reported.
Methods
Plant selection and collection
In the framework of a random study of Cameroonian
plants as sources of anti-malarial agents, the fruits of S.
juglandifolia were collected during the rainy season in Mt.
Kalla, Yaoundé area, Cameroon in October, 2010. The
plant sample was brought to the Laboratory for Phytobio-
chemistry and Medicinal Plants Studies, University of
Yaoundé I, Cameroon for phytochemical and biological
studies. Botanical identification was done at the National
Herbarium, Yaoundé by Mr. Victor Nana, where a voucher
specimen is deposited under the identification number
9176 SRFCam. The genus Sorindeia includes trees, shrubs
or lianas that are confined to tropical Africa, including
Madagascar, the Comoro Islands and the Mascarene
Islands [2]. Sorindeia juglandifolia is a tree of up to 23 m
height of which no specific use and no pharmacological
studies have been found. Therefore, the approach adopted
in this study differs from the reverse pharmacology ap-
proach [3], since there is no evidence of plant use against
malaria. A related species, Sorindeia mildbraedii, is used to
provide chewing sticks for oral hygiene [4].
Plant extraction and structure elucidation
Reagents and materials
Melting points were determined on a Büchi-540 melting
point apparatus. UV spectra were determined on a Spectro-
nic Unicam spectrophotometer. IR spectra were determined
on a JASCO Fourier Transform IR-420 spectrometer.1H- and 13C NMR spectra were run on a Bruker spectrom-
eter equipped with 5 mm 1H and 13C probes operating at
500 and 125 MHz, respectively, with TMS as internal
standard. Silica gel 230–400 mesh (Merck) and silica gel
70–230 mesh (Merck) were used for flash and column
chromatography, while precoated aluminum-backed silica
gel 60 F254 sheets were used for TLC. Spots were visualized
under UV light (254 and 365 nm) or using MeOH-H2SO4
reagent.
Extraction and fractionation
The ground fruits (2 kg) were extracted at room
temperature with methanol (2× 5 L, 48 h each). Solvent
was evaporated under reduced pressure to yield 28g of
extract. A portion (20g) of the extract was fractionated
by flash chromatography over silica gel (70–230 mesh,
Merck, 7 × 42 cm), eluting with a gradient of increasing
polarity of mixtures of hexane-ethyl acetate 100:0–0:100,
resulting in the collection of 35 fractions of 500mL each,
which were combined on the basis of TLC analysis to
yield 18 subfractions, labelled SJFR1-SJFR18. All these
fractions were tested in vitro against the Plasmodium
falciparum chloroquine-resistant W2 strain and the P.
falciparum cysteine protease falcipain-2.
Fractions SJFR8-10 [Hex:EtOAc (1:1)] and SJFR17-18
[Hex:EtOAc (0:1)] showed the best potencies against
falcipain-2 and P. falciparum W2, respectively. Subse-
quent TLC analysis suggested the combination of the re-
spective fractions into SJFRA and SJFRB, which were
submitted to phytochemical investigation.
Fraction SJFRA [7g, composed of subfractions 20–22,
obtained with Hex:EtOAc (1:1)] was subjected to
column chromatography over silica gel (230–400 mesh,
Merck, 5 × 42 cm), eluting with gradient mixtures of
hexane-ethyl acetate 30:70–80:20, resulting in 82 sub-
fractions of 200 mL, combined on the basis of TLC ana-
lysis into two subfractions, SJFRA1 (1–25) (3.8g), and
SJFRA2 (26–82) (0.3g).
Subfraction SJFRA1 showed significant anti-
plasmodial activity, and was, therefore, subjected to col-
umn chromatography over silica gel (230–400 mesh,
Merck, 5 × 42 cm), eluting with gradient mixtures of
hexane-ethyl acetate 30:70 – 20:80 to yield SJFRA1-41,
identified as 2,3,6-trihydroxy benzoic acid (1, 125mg).
Column chromatography over silica gel (230–400 mesh,
Merck, 5 × 42 cm) of SJFRB [6g, composed of subfractions
34–35, obtained with Hex:EtOAc (0:1)] eluting with gradi-
ent mixtures of hexane-ethyl acetate 80:20 – 0:100 and
EtOAc- MeOH (1:0 to 98:2) yielded SJFRB-41, identified as
2,3,6-trihydroxy methyl benzoate (2, 35mg).
Evaluation of biological activities
The protocol described in this report was approved by the
Institutional Review Board (IRB-No: 001/UY11 BTC/ IRBI
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Cameroon, and the World Health Organization Research
Ethics Review Committee (WHO ERC-A80689).
In vitro screening of Sorindeia juglandifolia extracts
against Plasmodium falciparum W2
Plasmodium falciparum strain W2, known to be resist-
ant to chloroquine and other anti-malarials [5], was cul-
tured in sealed flasks at 37°C, in a 3% O2, 5% CO2 and
91% N2 atmosphere in RPMI 1640, 25 mM HEPES, pH
7.4, supplemented with heat inactivated 10% human
serum and human erythrocytes to achieve a 2% haem-
atocrit. Serum and erythrocytes were purified from
blood voluntarily given by adults with no recent contact
with malaria, and who have signed an informed consent
form. Parasites were synchronized in the ring stage by
serial treatment with 5% sorbitol (Sigma) [6] and tested
at 1% parasitaemia. Stock solutions of plant extracts
were prepared as 1 mg/ml in DMSO, diluted as needed
for individual experiments, and tested in triplicate as
described previously [7,8]. The stock solutions were
diluted in supplemented RPMI 1640 medium so as to
have at most 0.2% DMSO in the final reaction medium.
Equal volumes (100μl) of inhibitors and 1% parasitaemia,
4% haematocrit culture were then added and gently
mixed thoroughly. Negative controls contained equal
concentrations of DMSO. Positive controls contained
1 μM chloroquine phosphate (Sigma). Cultures were
incubated at 37°C for 48 h. Parasites at the ring stage
were thereafter fixed by replacing the serum medium by
an equal volume of 1% formaldehyde in PBS. Aliquots
(5 μl) of each culture were then added to round-bottom
polystyrene 96 well plates containing 150 μl of 100 mM
NH4Cl, 0.1% Triton X- 100 and 1 nM YOYO-1 nuclear
dye (Molecular Probes) in PBS, and the parasitaemia of
treated and control cultures were compared using a
Becton-Dickinson FACSort flow cytometer equipped with
AMS-1 loader (Cytek Development) to count nucleated
(parasitized) erythrocytes. Data acquisition was performed
using Cell Quest software. These data were normalized to
percent control activity and 50% inhibitory concentra-
tions (IC50s ) were calculated using Prism 5.0 software
(GraphPad) with data fitted by nonlinear regression to
the variable slope sigmoidal dose–response formula,
y = 100/[1 + 10(logIC50− x)H] where H is the hill coefficient
or slope factor [5].
In vitro screening of Sorindeia juglandifolia extracts
against Plasmodium falciparum field isolates
Blood sampling and purification of Plasmodium
falciparum isolates
Plasmodium falciparum isolates were prepared as described
previously [9]. Blood was collected from outpatients present-
ing at the Etoug-Ebe Baptist Health Centre in Yaoundé withuncomplicated malaria. Patients older than five years of age
with mono infection with P. falciparum and parasite density
greater than 6,000 asexual parasites per microliter of blood
were considered for inclusion in the study. Those with re-
cent history of self-medication with anti-malarial drugs were
excluded. After patients agreed to participate in the study
and signed the consent form, 5 mL of blood was collected
from them by venipuncture into heparinized tubes. The
blood was centrifuged at 3,000 rpm for 15 min and the
supernatant discarded. The pellets were suspended in
10 mL of pre-warmed RPMI 1640 medium and centri-
fuged again twice at 3,000 rpm for 5 min, and the super-
natant was then discarded. The volume of the packed-cells
was estimated and mixed with an equal amount of RPMI
1640, 25 mM HEPES, pH 7.4, and subsequently used
at 4% haematocrit for experiments. Thin smears were
evaluated to assess the parasitaemia, the developmental
stages of parasites, and the colour, shape and size of red
blood cells. Nine such isolates were prepared and sub-
sequently used for experiments.
Evaluation of antiplasmodial activity
The activity of plant products was assessed as previously
described [9]. All the fractions and pure compounds that
showed activity against P. falciparum W2 and falcipain-2
were tested against the P. falciparum field isolates. Stock
solutions of plant extracts were prepared at 1 mg/ml in
DMSO and diluted as needed for individual experiments
in 96-well plates using RPMI 1640, to achieve a max-
imum final DMSO concentration of 0.2%. Chloroquine
was used as positive control at 1 μM, and the negative
control was an equal concentration of DMSO. To assess
the susceptibility of parasites to drugs, they were main-
tained in RPMI 1640 supplemented with 25 mM HEPES
buffer (pH 7.4), 0.05% ampicillin, and 10% AB+ human
serum at 37°C, in a candle jar. To achieve this, 200 μl
parasite suspensions at 4% haematocrit and 0.1%– 0.3%
parasitaemia were added to 50 μl of each concentration of
inhibitor in individual wells, each tested in triplicate. Cul-
tures were incubated at 37°C for 48 h in a candle jar. To
estimate the effects of inhibitors after 48 h, thin smears
from treated and control cultures were fixed in methanol
for 30 s, stained using fresh 5% Giemsa solution (Sigma)
in phosphate buffer (pH 7.1), and examined by counting
the parasitaemia per 100 erythrocytes. IC50s were calcu-
lated from curves plotting percent growth versus drug
concentration using Prism 5.0 software with data fitted by
nonlinear regression to the variable slope sigmoidal dose–
response formula y = 100/[1 + 10(logIC50− x)H], where H is
the Hill coefficient or slope factor [5].
Assessment of falcipain-2 inhibition by plant extracts
Falcipain-2 activity was measured as hydrolysis of
the fluorogenic substrate benzyloxycarbonyl-Leu-Arg-7-
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Fluoroskan II spectrofluorometer, as described previ-
ously [10]. For inhibitor assays, recombinant falcipain-
2 prepared as described previously [11] was incubated
with inhibitors (added from stocks concentrated 100-
to 1,000-fold in dimethyl sulfoxide [DMSO]) with 10
mM dithiothreitol, pH 5.5, for 30 min at room
temperature before the substrate (50 μM) was added.
Equal concentrations of enzyme were used for each
experiment. Multiple inhibitor concentrations were stud-
ied in triplicate, and the rates of hydrolysis were deter-
mined and compared to those of controls containing
equal concentrations of DMSO. All values were normal-
ized to the control activity, and IC50s were calculated
with the Prism 5.0 program, with data fitted by non-
linear regression.
In vivo assessment of 2,3,6-trihydroxy benzoic acid
against Plasmodium berghei
Compound 1 (2,3,6-trihydroxy benzoic acid), obtained
from the fractionation of S.juglandifolia extract, was
assessed in vivo using the Plasmodium berghei rodent
parasite model, according to the procedure described by
Okokon et al. [12] with a few modifications. Plasmo-
dium berghei strain B (MRA-406, MR4, ATCCW
Manassas Virginia) was obtained from BEI Resources
[13] and used for the experiments. Female Swiss albino
mice aged eight weeks and weighing ~20 g were used
for efficacy and toxicity experiments. These animals
were bred in the animal house of the Faculty of
Medicine, University of Yaoundé I. They were fed a
standard laboratory diet (S.P.C. Ltd., Bafoussam,
Cameroon) and given clean tap water ad libitum.
Animal welfare requirements were strictly considered
during the experiments, as described in the protocol
approved by the National Ethics Committee (Reg. No.
FWAIRB00001954). To start infections, a cryotube of
parasites was thawed and the undiluted contents were
injected immediately i.p. into naïve recipient mice.
Three days after infection, the parasitaemia was evalu-
ated daily in tail vein blood through Giemsa-stained
thin smear observation under oil immersion at 100X
magnification. Passage of infection into new mice
consisted of an i.p. injection of 200 μL of 106 infected
erythrocytes/mL sterile PBS. The test compound was
dissolved and diluted in Tween 20: Ethanol (7:3 v/v).
Evaluation of the suppressive effect of the compound
Preliminary screening of the compound consisted of a
suppressive test. To achieve this, animals were infected
i.p. with 200 μL of 106 infected erythrocytes/mL sterile
PBS. Four hours after infection, duplicate batches of ani-
mals were treated as follows: four batches of six mice
each were given test drug orally at respective dosages of10, 30, 50 and 100 mg/kg, and subsequently once daily
for four consecutive days. Negative controls consisted of
one batch of 6 infected mice receiving no drug (dose 0),
and one batch of six uninfected animals. Positive con-
trols consisted of one batch of infected mice receiving
quinine sulfate at 24 mg/kg.
Evaluation of the curative effect of the compound
Curative assays were subsequently conducted using the
same setting, with animal receiving drug at daily oral
dosages of 10, 30, 50 and 100 mg/kg for 5 consecutive
days, starting day 3 (72 hours) after infection. Thin
blood smears were made daily from the tail blood of
mice and the level of parasitaemia assessed by examin-
ation of Giemsa-stained smears using a microscope at
100X magnification. In both cases, activity was expressed
as ED50s that were calculated based on percent parasit-
aemia obtained 24 h after the last drug administration
using GraphPad Prism 5.0 software.
Evaluation of the acute toxicity of active extracts
The acute toxicity profile of the active fractions was
determined as previously described [6,8] and according
to the Organization for Economic Cooperation and
Development (OECD) protocol briefly described below,
with some modifications [14]. Before the experiments,
animals were starved for 12 h in wire mesh bottom
cages to prevent coprophagy but allowed free access to
water.
Mice were studied in groups of 6 animals (3 males and
3 females). They received the extract solutions in olive
oil per os in doses ranging from 1,000 to 7,000 mg/kg.
The negative control group received 1ml olive oil. The
animals were carefully observed for 2 h, and thereafter
for 7 days during which mortality, body weights and
gross behavioural changes were recorded daily.
Results and discussion
Phytochemical investigation of the fruit extract of
Sorindeia juglandifolia
The air-dried and ground fruits of S. juglandifolia were
extracted at room temperature using MeOH. The extract
was concentrated to dryness under vacuum and the resi-
due subjected to flash chromatography. Repeated column
chromatography of pooled fractions yielded two known
compounds, 2,3,6-trihydroxy benzoic acid (1), m/z= 170;
mp= 188.5-190; yellow crystals and 2,3,6-trihydroxy
methyl benzoate (2), m/z= 184; mp= 139–140.5; pale
yellow crystals with respective purification yields of
0.062% and 0.0017% relative to the weight of the starting
plant material (Figure 1). These two phenol derivatives
have not generally been obtained from natural sources,
but related compounds, such as gallic acid and deriva-
tives, are ubiquitous in the plant kingdom and readily
Table 1 Inhibition of Plasmodium falciparum W2 and











SJFR2 Hex:EtOAc 10% 11.55±2.45 6.02±3.81
SJFR3 >10 >10
SJFR4 >10 21.90 ±1.85










SJFR15 Hex:EtOAc 75% >10 17.31±2.51
SJFR16 >10 >10
SJFR17 8.47±0.41 1.12±0.16











13.04±1.63 μM 6.09±0.87 μM
IC50= Concentration that killed/inhibited 50% of parasites/enzyme relative to
negative control. S.D. = standard deviation, the drugs were tested in triplicate.
Positive controls were CQ = chloroquine, ART= artemisinin, and E-64 =
l-transepoxy-succinyl-leucylamido-(4-guanidino)-butane.
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compounds, fractions were afforded and were also tested
for anti-plasmodial activity.
In vitro activity of Sorindeia juglandifolia extracts against
Plasmodium falciparum W2 and recombinant falcipain-2
Results achieved from the in vitro assessment of plant
extracts are presented in Table 1. From these results, six
fractions (SJFR1, SJFR2, SJFR8, SJFR9, SJFR10, SJFR17,)
and seven fractions (SJFR1, SJFR2, SJFR4, SJFR9, SJFR15,
SJFR17, SJFR18) out of the 18 afforded through flash chro-
matography exerted inhibitory effects against P. falciparum
W2 strain and recombinant falcipain-2, respectively.
The IC50 values were 2.3-11.6 μg/ml for W2, and 1.1-21.9
μg/ml for falcipain-2. These activities support further in-
vestigation of the fractions to identify the active principles.
Detailed investigation of promising fractions afforded
2,3,6-trihydroxy benzoic acid (1) and 2,3,6-trihydroxy
methyl benzoate (2), which also showed inhibitory
effects in the low micromolar range, with IC50 values of
16.5 and 13.0 μM against Plasmodium falciparum W2,
and 35.4 and 6.1 μM against falcipain-2. The potency
exerted by the purified compounds confirms the
preliminary results obtained with fractions, suggesting
potent anti-malarial activity of natural products from
S. juglandifolia. Further studies are required to identify
the most potent active compounds from S. juglandifolia
and to determine the biochemical targets of these
compounds.
In vitro activity of Sorindeia juglandifolia extracts against
field strains of Plasmodium falciparum
The nine fractions that showed potency against P. falcip-
arum W2 strain and falcipain-2 (SJFR1, SJFR2, SJFR4,
SJFR8, SJFR9, SJFR10, SJFR15, SJFR17, and SJFR18) were
tested in vitro against fresh P. falciparum isolates
(Additional file 1). The results showed potent effects of
plant fractions against P. falciparum isolates. However,
results varied greatly from isolate to isolate, with IC50










Figure 1 Antiplasmodial compounds from the fruits of
Sorindeia juglandifolia (Anacardiaceae). Compounds 1 and 2
were isolated from the fruits of Sorindeia juglandifolia and
characterized by means of physico-chemical and spectroscopic
techniques and identified as 2,3,6-trihydroxy benzoic acid (1) and
2,3,6-trihydroxy methyl benzoate (2).potency against at least one P. falciparum isolate. Isolate
E01 was the most sensitive to all the fractions, with IC50
values below 1 μg/ml. Overall, SJFR10, SJFR17, and
SJFR18 inhibited all the nine isolates with IC50 ranging
from 0.20-16.44 μg/ml. The positive control (CQ) was ac-
tive against all the isolates, with IC50s from 16.6-38.4
ng/ml. Compounds (1) and (2) also showed activity against
all nine isolates, with IC50 values from 6.3- 36.1 μM.
Of note, the fresh P. falciparum isolates were 10–20
fold more sensitive to the tested fractions, compared to
the results obtained with the same fractions against the
W2 reference strain. Similar findings were recently
described, with variability of results in the assessment of
the anti-plasmodial activity of Cameroonian Annonaceae
plant extracts [9]. Overall, no significant changes were
observed in colour, shape and size of red blood cells of
treated mice relative to negative controls.
Figure 2 In vivo inhibitory effect of 2,3,6-trihydroxy benzoic
acid (1) against rodent malaria. Compound 2,3,6-trihydroxy
benzoic acid (1) was assessed for anti-plasmodial activity in vivo.
Suppressive and curative tests showed 50% suppressive and
effective doses of 44.9 and 42.2 mg/kg, respectively.
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Plasmodium berghei B
Compound 1, (2,3,6-trihydroxy benzoic acid), which
showed good potency in vitro against P. falciparum W2
and against falcipain-2 was assessed in vivo. In vitro
results were confirmed through assays using P. berghei
strain B that showed modest activity at doses ranging
from 10–100 mg/kg body weight (Table 2). When com-
pared to in vitro potency, this moderate activity of com-
pound (1) in vivo may be due to many parameters such
as bioavailability and metabolism that vary. Detailed
studies that include compound optimization, in vitro
and in vivo screening, and cytotoxicity study will indi-
cate further directions. Compound (1) exerted a dose-
dependent suppression of parasites when evaluated after
6 days (Figure 2). Similarly, parasite growth appeared to
be inhibited in a dose-dependent manner during the
5-day curative test (Figure 2). In these experiments the
50% suppressive dose and effective doses were 44.9 ± 1.6
mg/kg and 42.2 ± 1.6 mg/kg, respectively.
Toxicity profile of Sorindeia juglandifolia extracts
Promising extracts were assessed for acute toxicity
through oral administration in mice at doses of 1,000,
3,000, 5,000 and 7,000 mg/kg. Apart from transient
prostration and loss of appetite at doses of 5,000 and
7,000 mg/kg, no major behavioral changes among ex-
perimental animals were observed, and no deaths were
seen at doses ≤ 7,000 mg/kg body weight. This indicates
that LD50 values of tested fractions are > 7,000 mg/kg,
70–140 folds above doses with anti-plasmodial activity.
According to the OECD guidelines [14-16], these results
suggest that the fractions are safe.Table 2 In vivo anti-malarial activity of 2,3,6-trihydroxy
benzoic acid (1)
Drug dose (mg/kg) Mean % Suppression/Inhibition
Suppressive test
10 22.73
30 35.95 cSD50 = 44.9 ± 1.6 mg/kg
50 53.66
100 69.63
Quinine sulfate (24 mg/kg) 71.34
Curative test
10 20.95
30 41.00 cED50= 42.2 ± 1.6 mg/kg
50 57.27
100 66.40
Quinine sulfate (24 mg/kg) 89.50
cSuppressive/Effective dose at 50%= concentration of drug that cleared/
reduced parasitaemia by 50%. Percentages of inhibition were calculated based
on the parasitaemia obtained 24 h after the last drug administration.Conclusions
Sorindeia juglandifolia fruit extracts showed promising
anti-plasmodial properties in in vitro and in vivo experi-
ments. The present study also identified two active prin-
ciples: 2,3,6-trihydroxy benzoic acid and 2,3,6-trihydroxy
methyl benzoate with anti-malarial activity. These results
support further investigation of natural products from S.
juglandifolia for anti-malarial drug development. Within
this framework, further studies will focus on chemical
features of active principles from other promising frac-
tions, impact of fruit collection time on quality, quantity,
and activity of isolated metabolites, and the eventual re-
versal effect of active natural products on parasites re-
sistance to chloroquine in a clinical setting as previously
experimented by Willcox and Rasoanaivo [17].Additional file
Additional file 1: Inhibition of P. falciparum isolates by Sorindeia
juglandifolia fractions and purified compounds.
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